• OPEN AN ACCOUNT
Indian Indices
Sensex
74,781.76 -120.83
( -0.16%)
Global Indices
Nasdaq
52,596.82 511.72
(0.98%)
Dow Jones
7,678.62 65.92
(0.87%)
Hang Seng
63,979.83 -1,291.12
(-1.98%)
Nikkei 225
10,650.44 41.52
(0.39%)
Forex
USD-INR
95.45 0.39
(0.41%)
EUR-INR
110.95 0.35
(0.32%)
GBP-INR
129.16 0.36
(0.28%)
JPY-INR
0.62 0.00
(0.09%)

EQUITY - MARKET SCREENER

Wanbury Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524212
INE107F01022
41.3185648
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
WANBURY
14.11
837.46
EPS(TTM)
Face Value()
Div & Yield %
16.97
10
0
 

Wanbury explores new market opportunities for its new APIs
Jun 10,2026

Wanbury announced the company has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs).

For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore.

The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs.

Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.